Researchers unveiled a new CRISPR-based enzyme engineered to selectively destroy cancer cells by shredding their DNA at tumor-causing mutation sites. Early lab results show striking selectivity, sparing healthy tissue that lacks the target mutations.
The team says the approach could complement or replace some existing chemotherapies, but stresses that clinical trials in humans remain years away. Regulators are watching closely as gene-editing therapeutics inch further into oncology.
